Abstract

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count
Chetasi Talati ... Jeffrey E Lancet
Blood | VOL. 130
Chetasi Talati, et. al.Chetasi Talati ... Jeffrey E Lancet
25 Jun 2021
Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count
Chetasi Talati ... Jeffrey Lancet
Clinical Lymphoma & Myeloma | VOL. 18
Chetasi Talati, et. al.Chetasi Talati ... Jeffrey Lancet
28 Aug 2018
Different Treatment Approaches to Blast Phase-Myeloproliferative Neoplasms
Franco Castillo Tokumori ... Andrew T Kuykendall
Blood | VOL. 138
Franco Castillo Tokumori, et. al.Franco Castillo Tokumori ... Andrew T Kuykendall
05 Nov 2021
Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial
Andrew H Wei ... Gail J Roboz
Blood | VOL. 138
Andrew H Wei, et. al.Andrew H Wei ... Gail J Roboz
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis.
Ayalew Tefferi ... Tiziano Barbui
Blood | VOL. -
Ayalew Tefferi, et. al.Ayalew Tefferi ... Tiziano Barbui
08 Aug 2024
CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors.
Nayoung Kwon ... Diane S Krause
Blood | VOL. -
Nayoung Kwon, et. al.Nayoung Kwon ... Diane S Krause
05 Aug 2024
Asciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia – Results from the ASCEND Study
David T Yeung ... Timothy P Hughes
Blood | VOL. -
David T Yeung, et. al.David T Yeung ... Timothy P Hughes
05 Aug 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Esteban Arrieta-Bolaños ... Katharina Fleischhauer
Blood | VOL. -
Esteban Arrieta-Bolaños, et. al.Esteban Arrieta-Bolaños ... Katharina Fleischhauer
05 Aug 2024
View more papers